KMDA Stock Earnings: Kamada Misses EPS, Misses Revenue for Q1 2024 Kamada (NASDAQ: KMDA ) just reported results for the first quarter of 2024. Kamada reported earnings per share of 4 cents. This was below the analyst estimate for EPS of 6 cents. The company reported revenue of $37.74 million. This was 0.72% worse than the analyst estimate for revenue of $38.01 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.
Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript Kamada Ltd. (NASDAQ:KMDA ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good morning, ladies and gentlemen, and welcome to the Kamada Limited First Quarter 2024 Earnings Conference Call.
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2024.
Kamada Ltd. Q1 Financial Results and Conference Call Kamada Ltd (IL:KMDA) has released an update. Kamada Ltd., a leading biopharmaceutical company, will unveil its financial outcomes for Q1 2024 on Ma…
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024.
Earnings call: Kamada Ltd. sees growth and optimistic 2024 outlook https://www.investing.com/news/stock-market-news/earnings-call-kamada-ltd-sees-growth-and-optimistic-2024-outlook-93CH-3329158
Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET